The tangarahu kwanan nan an ba da rahoton cewa an gaya wa jama'a su daina shan tari da magungunan sanyi saboda fargabar aminci game da maganin, pholcodine, maganin tari na opioid.
An cire 20 daga cikin maganin tari da sanyi na yau da kullun, gami da capsules na Nurse Day da Dare, cikin gaggawa daga kasuwa bisa odar masu kula da miyagun ƙwayoyi saboda damuwa game da haɗarin “sauri mai wuya” na anaphylaxis, bala'i mai haɗari mai haɗari.
Sanarwar 'Class 2 Medicine Recall' da aka karɓa daga gwamnatin Burtaniya yanar, an nuna a kasa.
Idan ya zo ga rigakafin mRNA COVID-19, ƙa'idodin ƙa'idodi biyu ba su taɓa fitowa fili ba.
An gano anaphylaxis a matsayin muhimmiyar haɗari ta Hukumar Kula da Magunguna ta Turai, tun daga Disamba 2020, a cikin EMA's CHMP (Kwamitin Samfuran Magunguna don Amfanin Dan Adam) rahoton kima akan maganin Pfizer-BioNTech COVID-19, wanda aka gani a ƙasa.
Hakanan, a cikin Sabunta Tsaro na lokaci-lokaci na farko na EU Rahoton, wanda nake da shi a baya bincikar, an sake nuna anaphylaxis a matsayin muhimmiyar haɗarin da aka gano.
A cikin wannan rahoton farmacovigilance, 3,827 da suka dace (mutane) an gano su, daga bayanan ba da izini. Kasar da aka fi samun matsalar ita ce Japan, sai Amurka da Birtaniya.
Mafi yawan adadin wadanda suka kamu da cutar sun hada da mata, lamarin da ya girgiza mutane 3,182 idan aka kwatanta da 454 na maza, tare da matsakaicin shekaru 44. Kasancewar sau 7 fiye da kamuwa da cutar ga mata ba sabon abu bane. Komawa cikin Disamba 2021, I bincikar Pfizer ya shirya Daftarin aiki na FDA, wanda ke rufe lokacin watanni 3, Dec 2020 zuwa Fabrairu 28, 2021 - a cikin yanayin anaphylaxis- mata sun fi shafa sau 8.
Don haka, kashi 98 cikin ɗari na abubuwan da suka dace (ciki har da halayen anaphylactic, girgiza anaphylactic, halayen anaphylactic da girgiza anaphylactic) an rarraba su da tsanani!
Bugu da ƙari, na kashi 92 cikin ɗari na abubuwan da suka faru, lokacin da ya wuce don wani mummunan al'amari ya faru bayan gudanar da maganin rigakafi, bai wuce sa'o'i 24 ba.
Sakamakon m
Daga cikin abubuwan 3,922, 28 sun mutu kuma ga 704 mai ban mamaki, ba a san sakamakon ba. Ba a bayar da lambobin shari'a don sakamako mai muni ba.
Laifukan ta rukunin shekaru
Daga cikin shari'o'in 3,827 masu dacewa (mutane), 23 sun fito ne daga rukunin shekarun yara da 3,021 daga rukunin shekarun manya.
Kasancewar cututtuka
Abin lura shine kusan kashi 2/3 na duk anaphylaxis sun yi ba suna da wasu cututtuka (al'amurran kiwon lafiya na asali).
Ganin abin da ya faru tun lokacin da aka fitar da rigakafin mRNA COVID-19, ba abin mamaki ba ne a karanta: "ba a gano sabon bayanin tsaro ba dangane da hadarin anaphylaxis tare da BNT162b2" (Pfizer-BioNTech COVID-19 allurar). Dalilin da aka bayar (ko uzurin da suke boye a baya) shine 'wannan hadarin ana sanar da shi.
A karkashin Dokar 174, Bayani ga Ma'aikatan kiwon lafiya na Burtaniya, wanda aka sabunta ta ƙarshe a cikin Dec 2021, an faɗi mai zuwa:
n gaskiya, a kan sosai rana ta farko na Pfizer-BioNTech COVID-19 allurar rigakafin cutar a Burtaniya, an sami rahotanni guda biyu na anaphylaxis da ɗayan da aka ruwaito na yiwuwar rashin lafiyan. Wannan bai hana MHRA daga tunawa da samfurin ba - kawai sun kawar da batun ta hanyar bayyana cewa mutanen da ke da tarihin rashin lafiyar kada su dauki maganin.
Ko da a lokacin da suka sani- Pfizer/BioNTech's lipid nanoparticle sinadaran ALC-0159 da ALC-0315 ba a taɓa haɗa su cikin kowane magani mai lasisi ba. ALC-0159 ya ƙunshi PEG (Polyethylene glycol) wanda shine an san yana haifar da anaphylaxis.
Ba shi da shakka: anaphylaxis sanannen bala'i ne mai barazanar rai, kusan lokaci guda an ba da izinin amfani da gaggawa don rigakafin Pfizer-BioNTech COVID-19. Amma duk da haka, saboda “alurar riga-kafi ce” ko ta yaya ta sami izinin wucewa kyauta daga duk masu kula da magunguna, komai yawan bayanan da suka taru, lokacin da aka tuno da maganin tari ko capsule a daya bangaren cikin gaggawa bisa “haɗarin anaphylaxis da ba kasafai ba.”
An sake bugawa daga marubucin Mayarwa
-
Sonia Iliya tana da kwarewa a fannin Tattalin Arziki. Tsohuwar mai binciken BBC ce kuma yanzu tana aikin jarida mai bincike.
Duba dukkan posts
